As we observe a significant decrease in cellular proliferation in our NSCLC cell lines at concentrations as low as 100 nM, particularly for those cells that express significant levels of IL-23R (A549), potential clinical efficacy may be achieved using this dose. Here, IL23R is linked to non-small cell lung carcinoma.